We studied whether
enprostil, a
synthetic prostaglandin E2 derivative, might inhibit
gastrin release and the trophic effects on gastric oxyntic mucosa induced by prolonged treatment with an inhibitor of
hydrogen-
potassium-stimulated
adenosine triphosphatase, the substituted
benzimidazole BY 831-78. Rats were treated intragastrically with
enprostil (1 or 15 micrograms/kg b.i.d.),
BY 831-78 (15 mumol/kg once daily), the combination of
enprostil and
BY 831-78,
ranitidine (300 mumol/kg b.i.d.), and placebo. Plasma
gastrin and
somatostatin levels and gastric acid secretion were measured during a 1-day treatment in animals fitted with chronic gastric
fistulas and repeatedly during 9 wk of treatment in intact rats. Despite inhibiting
acid secretion,
enprostil did not increase plasma
gastrin. When combined with
BY 831-78,
enprostil transiently reduced the BY 831-78-induced increase of integrated plasma
gastrin (1375 +/- 206 vs. 2137 +/- 256 pmol/L.12 h, p less than 0.05) in fasted rats with
fistulas, but failed to prevent the marked hypergastrinemia following 9 wk of treatment with
BY 831-78 (717 +/- 80 vs. 731 +/- 56 pmol/L) in intact rats. However,
enprostil reduced the BY 831-78-induced increase of oxyntic mucosal volume (458 +/- 31 vs. 567 +/- 33 mm3, p less than 0.01), whereas
BY 831-78 prevented the
enprostil-induced increase of
antral mucosal volume (42 +/- 3 vs. 56 +/- 3 mm3, p less than 0.01). These results demonstrate that some of the trophic effects induced by a
hydrogen-
potassium-stimulated
adenosine triphosphatase inhibitor are not exclusively governed by
gastrin.